Eurofins sharpens focus on life sciences with buybacks and deals
Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.
This is the period's core company result and the main fundamental driver of the stock.
Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.
Buybacks are a repeated but still active capital-return signal that helps explain price support.
Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.
These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.
Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.
This is the period's main demand-side signal for Eurofins' core testing business.